Compositions, kits, and methods for detecting preclinical alzheimer's disease

A composition comprising:

• a first binding agent for CD91 conjugated with a first detectable moiety;
• a second binding agent for CD59 conjugated with a second detectable moiety;
• and
• a third binding agent for CD163 conjugated with a third detectable moiety.

A method for diagnosing AD in a human patient, comprising:

• obtaining a blood sample from the human patient;
• optionally storing the blood sample in ice;
• optionally testing the blood sample within three hours of obtaining the blood sample;
• reacting the blood sample with
• a mouse anti-human IgG monoclonal antibody for CD91 conjugated with a first fluorophore to obtain bound CD91;
• a mouse anti-human IgG monoclonal antibody for CD59 conjugated with a second fluorophore to obtain bound CD59;
• a mouse anti-human IgG monoclonal antibody for CD163 conjugated with a third fluorophore to obtain bound CD163;
• measuring a concentration of bound CD91, a concentration of bound CD59, and a concentration of bound CD163 in the blood sample by fluorescence of the first fluorophore, the second fluorophore, and the third fluorophore;
• observing an increase in the concentration of bound CD91 relative to a concentration range of CD91 in healthy humans;
• observing an increase in the concentration of bound CD59 relative to a concentration range of CD59 in healthy humans;
• observing a decrease in the concentration of bound CD163 relative to a concentration range of CD163 in healthy humans;
• thereby diagnosing AD in the human patient.